(INTREPID-1) A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

A study evaluating two new formulations of oprozomib plus pomalidomide and dexamethasone in participants with relapsed refractory multiple myeloma.

Start Date17 Jan 2017

Sponsor / Collaborator

Amgen, Inc.

NCT02227914

/ WithdrawnPhase 1/2

Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

The purpose of Phase 1b of the study is to determine the maximum tolerated dose, pharmacokinetics (PK) and pharmacodynamics (PDn) and assess the safety, tolerability and activity of oprozomib in combination with sorafenib in subjects with advanced hepatocellular carcinoma (HCC).
The purpose of Phase 2 of the study is to evaluate the efficacy of oprozomib in combination with sorafenib versus sorafenib alone and to compare the key outcome measures for subjects with advanced HCC.

Start Date01 Dec 2014

Sponsor / Collaborator

Amgen, Inc.

NCT02244112

/ TerminatedPhase 1

A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies

The purpose of this Phase 1 of the study is to evaluate the effect of food on the pharmacokinetics (PK) of oprozomib, the drug-drug interaction of oprozomib with midazolam, and the safety and tolerability of oprozomib in patients with advanced malignancies

Start Date01 Aug 2014

Sponsor / Collaborator

Amgen, Inc.

100 Clinical Results associated with Oprozomib

100 Translational Medicine associated with Oprozomib

100 Patents (Medical) associated with Oprozomib

131

Literatures (Medical) associated with Oprozomib

01 Mar 2025·JOURNAL OF EUKARYOTIC MICROBIOLOGY

Effect of protease inhibitors on the intraerythrocytic development of Babesia microti and Babesia duncani, the causative agents of human babesiosis

Article

Author: Jose Thekkiniath ; Temitope Aderanti ; Jordan M. Marshall

Abstract:

Human babesiosis is a malaria‐like, tick‐borne infectious disease with a global distribution. Babesiosis is caused by intraerythrocytic, apicomplexan parasites of the genus Babesia. In the United States, human babesiosis is caused by Babesia microti and Babesia duncani. Current treatment for babesiosis includes either the combination of atovaquone and azithromycin or the combination of clindamycin and quinine. However, the side effects of these agents and the resistance posed by these parasites call for alternative approaches for treating human babesiosis. Proteases play several roles in the context of parasitic lifestyle and regulate basic biological processes including cell death, cell progression, and cell migration. Using the SYBR Green‐1 assay, we screened a protease inhibitor library that consisted of 160 compounds against B. duncani in vitro and identified 13 preliminary hits. Dose response assays of hit compounds against B. duncani and B. microti under in vitro conditions identified five effective inhibitors against parasite growth. Of these compounds, we chose ixazomib, a proteasome inhibitor as a potential drug for animal studies based on its lower IC50 and a higher therapeutic index in comparison with other compounds. Our results suggest that Babesia proteasome may be an important drug target and that developing this class of drugs may be important to combat human babesiosis.

23 Feb 2025·Leukemia & Lymphoma

Ixazomib-induced thrombotic microangiopathy resolving without complement pathway inhibition: a case report

Article

Author: Wakefield, Harry ; Lafont, Tanguy ; Booth, Stephen

17 Jan 2025·ACS Chemical Biology

Functional Characterization of Pathway Inhibitors for the Ubiquitin-Proteasome System (UPS) as Tool Compounds for CRBN and VHL-Mediated Targeted Protein Degradation

Article

Author: Müller, Susanne ; Menge, Amelie ; Knapp, Stefan ; Robers, Matthew B. ; Schwalm, Martin P. ; Elson, Lewis ; Greco, Francesco A.

Small molecule degraders such as PROteolysis TArgeting Chimeras (PROTACs) and molecular glues are new modalities for drug development and important tools for target validation. When appropriately optimized, both modalities lead to proteasomal degradation of the protein of interest (POI). Due to the complexity of the induced multistep degradation process, controls for degrader evaluation are critical and commonly used in the literature. However, comparative studies and evaluations of cellular potencies of these control compounds have not been published so far. Here, we investigated a diverse set of ubiquitin pathway inhibitors and evaluated their potency and utility within the CRBN and VHL-mediated degradation pathway. We used the HiBiT system to measure the level of target rescue after treatment with the control compounds. In addition, the cell health was assessed using a multiplexed high-content assay. These assays allowed us to determine nontoxic effective concentrations for control experiments and to perform rescue experiments in the absence of cellular toxicity.

News (Medical) associated with Oprozomib

25 Sep 2025

·www.einpresswire.com

Unfolded Protein Response pathway offers new targets to treat bone weakness in cancer patients

New drugs that modulate protein processing in bone cells may prevent bone weakening and limit the growth of bone-localized tumors CHINA, September 25, 2025 / EINPresswire.com / -- The unfolded protein response (UPR) is a protective pathway that helps cells manage stress during protein production. Cancer cells exploit this system to survive harsh tumor environments. In bones, they also disrupt the balance of bone-building and bone-resorbing cells, leading to skeletal fragility. Emerging therapies that target the UPR show promise in restoring bone health while selectively killing malignant cells, offering new hope for patients with cancer-associated bone disease. Before a chain of amino acids can become an active and useful protein, it must be processed and folded into the appropriate conformation. Much of this processing occurs in the endoplasmic reticulum (ER) of every cell. However, any disruptions in protein homeostasis can be very stressful to the ER, and when the ER gets overwhelmed, a safety system called the Unfolded Protein Response (UPR) engages to slow down protein synthesis and allow the ER to catch up. If a temporary slowdown of protein synthesis isn’t enough to restore normal ER function, the UPR triggers cell death. In many types of cancerous cells, the UPR response is altered to prevent cell death and drive the relentless growth that characterizes malignancy. These changes allow cancerous cells to tolerate the low oxygen and low nutrient environment of a tumor and continue to multiply. Drugs and therapies that target parts of the UPR pathway could therefore be effective against several types of cancers. Professor Sarah A. Holstein and Dr. Molly E. Muehlebach from the University of Nebraska Medical Center have thoroughly examined how the UPR pathway relates to cancer-induced damage in bones. In their review paper published online on 28 August 2025 in Bone Research , Prof. Holstein and Dr. Muehlebach examined existing research on how the UPR pathway is deeply connected with the differentiation of cells in bone tissue, the maintenance and renewal of bones, and how infiltration of bone by cancerous cells hijacks the UPR pathway to cause structural weakening of bone. This occurs for cancers such as osteosarcoma and Ewing sarcoma (primary bone cancers), as well as blood cancers like multiple myeloma and solid tumors that metastasize to bone, such as breast or prostate cancer. Discussing the importance of this research, Prof. Holstein says, “Disruption of the remodeling cycle can result in bone loss or increased bone density. However, in both cases, the bone is brittle and can easily fracture. As a result, skeletal structure and integrity is compromised, significantly contributing to disease morbidity and negatively impacting overall patient survival in cancer-induced bone disease.” In their paper, Prof. Holstein and Ms. Muehlebach first look at the three primary UPR pathways – Eukaryotic translation Initiation Factor 2 Alpha Kinase 3 (EIF2AK3); ER to Nucleus signaling 1 (ERN1); Activating Transcription Factor 6 (ATF6) and their downstream cascades. They then describe the specific roles of many UPR-associated proteins in the differentiation of osteoblasts (bone-building) and osteoclasts (bone-dissolving) cells from skeletal stem cells. Healthy bones require both kinds of cells to work in an optimal fashion. However, when cancerous cells invade bone tissue, they induce UPR-associated dysfunction of osteoclasts, osteoblasts, or both, resulting in bones that are either weak due to lack of density or brittle due to excessive mineralization. These phenomena are termed “skeletal related events” (SREs). Emerging classes of drugs may reduce SREs by targeting specific aspects of each of the three UPR cascades and their downstream proteins. The mechanisms of action against SREs include: • Inhibiting EIF2AK3 (e.g. GSK2606414) • Inhibiting ERN1 (e.g. Sunitinib malate, Toyocamycin) • Inhibiting disruption of ER associated protein degradation (e.g. VCP inhibitors such as CB-5083) • Enhancing chaperone proteins to increase folding rates and relieve ER stress (e.g. Sodium phenylbutyrate) Other emerging drugs with high affinity for bone tissue induce UPR-mediated apoptosis in malignant cells by: • Disrupting the synthesis of isoprenoids needed for protein processing (e.g. bispho- sphonates zoledronic acid (ZA), RAM2061) • Disrupting the degradation of unfolded proteins (e.g. Oprozomib) All of these drugs are at various stages of in vitro, animal, or early human trials, and show various degrees of promise in alleviating SREs and killing tumors localized in bones. Much work remains to be done, however, to ensure that these UPR modulating drugs act in a targeted manner against cancerous cells, and do not disrupt other functions within bone or other tissues. As Prof. Holstein concludes, “Ultimately, the success of UPR modulators in treating cancer-related bone disease will depend on developing agents that specifically target bone and tumor cells while minimizing effects on healthy tissue.” *** Reference Title of original paper: The role of the Unfolded Protein Response pathway in Bone Homeostasis and potential therapeutic target in Cancer-associated Bone Disease Journal: Bone Research Authors: Molly E. Muehlebach and Sarah A. Holstein DOI: 10.1038/s41413-025-00457-6 About the University of Nebraska Medical Center Established in 1869, the University of Nebraska Medical Center (UNMC) is a public research university and health center located in Omaha, NE, USA. The university currently houses a hospital as well as colleges for dentistry, pharmacology, nursing, medicine, public health and allied health professions. In recent years, UNMC was involved at the forefront of the United States’ response to the 2014 Ebola epidemic and the 2020 SARS-CoV-2 pandemic. As of 2025, UNMC serves over 4,000 students and has strong research links with other institutions in the University of Nebraska system. Website: https://www.unmc.edu/ About Professor Sarah A. Holstein from the University of Nebraska Medical Center Prof. Sarah A. Holstein is a Professor in the Division of Oncology and Hematology at the University of Nebraska Medical Center (UNMC). She completed her MD and PhD, as well as clinical training in hematology/oncology from the University of Iowa (UI), before serving as a faculty member at the UI and then Roswell Park Comprehensive Cancer Center. She joined the faculty at UNMC in 2016. Her basic science, translational and clinical research focuses on multiple myeloma. Prof. Holstein has published over 140 research articles and book chapters. In addition to her research, she serves on the International Myeloma Working Group as well as several national myeloma committees and is an Associate Editor for Clinical Pharmacology and Therapeutics. Yini Bao Bone Research Editorial Office +862885546461 ext. email us here Visit us on social media: X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

07 Jun 2010

·www.biospace.com

Onyx Pharmaceuticals, Inc.'s Carfilzomib Continues to Demonstrate Encouraging Results in Ongoing Phase 2 Multiple Myeloma Study

EMERYVILLE, Calif., June 5 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced interim results from an ongoing Phase 2 study, known as the 004 study. Carfilzomib, a selective, next-generation proteasome inhibitor, demonstrated encouraging overall response rates (ORR), tolerability and durable disease control when administered as a single-agent in patients with relapsed and/or refractory multiple myeloma. In 53 evaluable patients who had not been previously treated with bortezomib (Velcade®), carfilzomib achieved an overall response rate of 55 percent at 27mg/m2. Patients in this group also achieved time-to-progression (TTP) of 11.5 months and duration of response (DOR) of 11.5 months. Forty percent of patients were refractory to their most recent therapy prior to entering the trial. Overall response is defined as a partial response or greater.(i) These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Ravi Vij, M.D., Associate Professor, Department of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia Section at the Washington University School of Medicine. "Although there are no direct comparative studies, based on historical controls, carfilzomib is exhibiting one of the highest single agent response rates and longest durations of response in patients with multiple myeloma who have had one to three prior therapies in this ongoing Phase 2 study," said Dr. Vij. "The data from this trial support carfilzomib's potential to benefit patients with multiple myeloma who are no longer responding to current therapies." One hundred fifty-five patients with relapsed and/or refractory multiple myeloma were enrolled in the study and were divided into two populations: patients who had not received prior bortezomib treatment (bortezomib-naive) and those who had received prior bortezomib treatment (bortezomib-treated). Of the 119 bortezomib-naive patients, 53 evaluable patients received carfilzomib at 27mg/m2 and 53 evaluable patients received carfilzomib at 20mg/m2. On the bortezomib-treated arm, 34 evaluable patients received carfilzomib at 20mg/m2 and were not dose escalated. The 53 evaluable bortezomib-naive patients who received carfilzomib at 20mg/m2 achieved an ORR of 45 percent. Other interim results at the 20mg/m2 included TTP of 8.3 months and DOR of 10.2 months. Forty-nine percent of these patients were refractory to their most recent therapy prior to entering the trial. The 34 evaluable patients previously treated with bortezomib achieved an ORR of 21 percent when treated with carfilzomib at the 20mg/m2 dose. Secondary endpoints included TTP of 8.1 months and DOR of 11.5 months. Forty-two percent of these patients were refractory to their most recent therapy prior to entering the trial. In the overall study population, treatment with carfilzomib was well-tolerated, and no new or unexpected adverse events occurred. The most common Grade 3 treatment-emergent adverse events included: pneumonia (11 percent), anemia (9.7 percent), neutropenia (9.7 percent) and thrombocytopenia (9 percent). Peripheral neuropathy of any grade was infrequent and no Grade 4 adverse events were observed. "This data from the 004 study will be included in the planned U.S. New Drug Application (NDA) that we intend to year-end 2010, pending top-line data from the ongoing registration trial, known as the 003-A1 study. The results from 003-A1, a Phase 2b trial, will form the basis for the NDA, which we expect to the accelerated approval mechanism," stated Michael Kauffman, M.D., Ph.D., Chief Medical Officer at Onyx. "In addition, we have announced our intention to initiate an international Phase 3 clinical trial evaluating carfilzomib in combination with lenalidomide and low dose dexamethasone in earlier stage myeloma. This trial is being conducted through a Special Protocol Assessment with the U.S. Food and Drug Administration and with Scientific Advice from the European Medicines Agency." Phase 2 004 Trial Design The open-label, single agent ongoing Phase 2 study, known as the 004 study, is being conducted in collaboration with the Multiple Myeloma Research Consortium, and enrolled approximately 150 patients with relapsed and/or refractory multiple myeloma who have received 1-3 prior treatments. Patients include two populations: bortezomib-naive patients with relapsed and/or refractory multiple myeloma and bortezomib-treated patients with relapsed and/or refractory multiple myeloma. Prior therapies include alkylating agents, stem cell transplant, thalidomide, lenalidomide and anthracyclines, and bortezomib in the bortezomib-treated patients. The primary endpoint is ORR and secondary endpoints include TTP, DOR, overall survival and safety. About the Carfilzomib Development Program Carfilzomib is a selective, next-generation proteasome inhibitor that is being investigated in a broad clinical trial program in multiple myeloma. The pivotal Phase 2b monotherapy study, also known as 003-A1, enrolled patients with relapsed/refractory multiple myeloma. Top-line results, expected in mid-2010, may support the filing of a U.S. New Drug Application (NDA) by year-end 2010. A Phase 3 clinical trial evaluating the combination of lenalidomide and low dose dexamethasone with or without carfilzomib in patients with relapsed multiple myeloma is expected to begin shortly. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the 009 trial. Carfilzomib is also being evaluated in advanced solid tumors. A second Phase 3 European clinical trial of carfilzomib is planned in relapsed/refractory myeloma and is designed to support a registrational filing with the EMA. Carfilzomib is also being evaluated in advanced solid tumors. About Multiple Myeloma Multiple myeloma is the second most common hematologic cancer and results from an abnormality of plasma cells, usually in the bone marrow. In the U.S., more than 50,000 people are living with multiple myeloma and approximately 20,000 new cases are diagnosed annually.(ii) According to estimates by the European Network of Cancer Registries, there are 21,420 new cases of multiple myeloma in Europe each year and around 15,000 deaths from this illness. It is estimated that 60,000 people in Europe are currently living with this disease. Worldwide, more than 180,000 people are living with MM and approximately 86,000 new cases are diagnosed annually.(iii) About Onyx Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, a targeted alpha-folate inhibitor, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at . Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals. Forward-Looking Statements This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the progress and results of the clinical development, safety, regulatory processes, commercialization efforts or commercial potential of carfilzomib. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related to the development and commercialization of pharmaceutical products. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2009, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law. (i) Partial response is defined by greater than or equal to 50% reduction of serum M-protein and reduction in 24 hour urinary M-protein by greater than or equal to 90% or to < 200 mg per 24 hours, International Uniform Response Criteria for Multiple Myeloma Published in Leukemia (2006) 20:1467-1473) with an Erratum in Leukemia (2007)21:1134-1135 (ii) National Cancer Institute, Surveillance Epidemiology and End Results, 2007 Facts and Figures (iii) International Agency for Research on Cancer, GLOBOCAN 2002 database SOURCE Onyx Pharmaceuticals, Inc.

CollaborateAntibodyFinancial StatementSmall molecular drugASCO

100 Deals associated with Oprozomib

External Link

KEGG	Wiki	ATC	Drug Bank
D10318	Oprozomib	-	DB11991

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Hepatocellular Carcinoma	Phase 2	United States	Amgen, Inc.	01 Dec 2014
Multiple Myeloma	Phase 2	Greece	Amgen, Inc.	01 Jan 2014
Multiple Myeloma	Phase 2	Italy	Amgen, Inc.	01 Jan 2014
Multiple Myeloma	Phase 2	Netherlands	Amgen, Inc.	01 Jan 2014
Refractory Multiple Myeloma	Phase 2	United States	Amgen, Inc.	02 Jul 2013
Refractory Multiple Myeloma	Phase 2	France	Amgen, Inc.	02 Jul 2013
Relapse multiple myeloma	Phase 2	United States	Amgen, Inc.	02 Jul 2013
Relapse multiple myeloma	Phase 2	France	Amgen, Inc.	02 Jul 2013
Waldenstrom Macroglobulinemia	Phase 2	United States	Amgen, Inc.	15 Oct 2011
Hematologic Neoplasms	Phase 2	United States	Amgen, Inc.	15 Oct 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01999335 (CTgov)	Phase 1	Multiple Myeloma	33	Pomalidomide+Dexamethasone+Oprozomib (Oprozomib 150 mg 5/14 + Pomalidomide 4 mg + Dexamethasone)	oqfnksailq = fdgvmoescc gjlutnrcmy (etppmfqmdq, sifeymvexm - mshaefrgsk) View more	-	27 Apr 2021
				Pomalidomide+Dexamethasone+Oprozomib (Oprozomib 150 mg 5/14 + Pomalidomide 2 mg + Dexamethasone)	oqfnksailq = yaixzxemhg gjlutnrcmy (etppmfqmdq, odhfpafzas - xpgvpfonth) View more
NCT01881789 (CTgov)	Phase 1/2	Multiple Myeloma	22	Lenalidomide+Dexamethasone+Oprozomib (Oprozomib 150 mg 5/14 + Lenalidomide + Dexamethasone)	iofkdxeudk = endpdpbtlf iwbudbntbw (pitlolxgnu, ervpkyiarq - vfmbdnbasq) View more	-	03 Mar 2021
				Lenalidomide+Dexamethasone+Oprozomib (Oprozomib 180 mg 5/14 + Lenalidomide + Dexamethasone)	iofkdxeudk = wdtpumfbyo iwbudbntbw (pitlolxgnu, pkblwomzgb - dexhchafua) View more
NCT01832727 (Pubmed \| Leuk Res) Manual	Phase 1/2	Multiple Myeloma	65	Oprozomib+dexamethasone (5/14 schedule)	zdqlfvloef(uzqfoxcgho) = pwqxbryfyn nskltpvtgn (dqdaajljew ) View more	Positive	01 Aug 2019
				Oprozomib+dexamethasone (2/7 schedule)	yeqedvqyie(ngdeprvpgn) = cinqeqkpwq edzwfbknuu (pymlavbgmi ) View more
NCT01129349 (Pubmed \| Invest New Drugs) Manual	Phase 1	Advanced Malignant Solid Neoplasm	44	oprozomib (escalating once daily)	jssnhcztze(nlhxxletpc) = kulpgliibq uyexpnpmvp (vrhhqmowmc ) View more	Negative	01 Apr 2016
				oprozomib (split dose)	jssnhcztze(nlhxxletpc) = nztfbwxjvc uyexpnpmvp (vrhhqmowmc ) View more
NCT01999335 (ASH 12015 \| ASH 22015) Manual	Phase 1	Multiple Myeloma	21	Pomalidomide+Dexamethasone+Oprozomib (5/14 schedule)	gynncthtyo(xyzuhwmgwt) = vpkfrkaikg rzwhlkslwj (povttagqsy )	Positive	03 Dec 2015
				Pomalidomide+Dexamethasone+Oprozomib (2/7 schedule)	gynncthtyo(xyzuhwmgwt) = oaibkawjbc rzwhlkslwj (povttagqsy )
NCT01416428 (EHA2015)	Phase 1/2	Hematologic Neoplasms \| Multiple Myeloma First line	19	OPZ 240 mg/d (2/7 schedule)	jqqrkvfvkw(jhabdrpolu) = Common grade ≥3 AEs in both treatment schedules included diarrhea, nausea, and vomiting yrvkjetxqc (zxfrhkyhcr )	-	21 May 2015
				OPZ 180 mg/d (5/14 schedule)
NCT01416428 (EHA2015)	Phase 1/2	Waldenstrom Macroglobulinemia	129	Single-agent Oprozomib	dheklbvwfj(vlwzdnfcwb) = amaiohkyxe irdtlollmj (wayphnwbvp )	-	21 May 2015
ASCO2012	Phase 1	Relapsed Solid Neoplasm	13	ONX0912 60 mg BID	umnprdkmei(ksdhdusdep) = pwubxxuawc forgwhbucy (htumxccjxp )	-	20 May 2012
ASCO2011	Phase 1	Relapsed Solid Neoplasm	18	ONX 0912	yabbdpziww(cscubhaetp) = jvqinfucxk cwpfsrabco (ftsurmxbew ) View more	-	20 May 2011

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis